Perspective Therapeutics (NYSE:CATX) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Perspective Therapeutics (NYSE:CATXFree Report) in a report issued on Tuesday morning, Benzinga reports.

Other analysts have also issued research reports about the stock. Royal Bank of Canada reiterated an outperform rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a research note on Friday, June 14th. Oppenheimer reaffirmed an outperform rating and issued a $15.00 price target (up from $12.00) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley increased their price target on Perspective Therapeutics from $12.00 to $17.00 and gave the stock a buy rating in a research report on Tuesday, April 9th. Finally, Lifesci Capital reissued an outperform rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $19.00.

Check Out Our Latest Research Report on CATX

Perspective Therapeutics Stock Performance

Shares of CATX opened at $10.68 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATXGet Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. The company had revenue of $0.33 million for the quarter. Equities research analysts predict that Perspective Therapeutics will post -1.05 earnings per share for the current year.

Insider Activity

In related news, Director Robert F. Williamson III bought 3,003 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was acquired at an average cost of $13.30 per share, with a total value of $39,939.90. Following the purchase, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Perspective Therapeutics news, Director Robert F. Williamson III bought 3,003 shares of Perspective Therapeutics stock in a transaction on Wednesday, May 29th. The shares were bought at an average price of $13.30 per share, for a total transaction of $39,939.90. Following the completion of the transaction, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert F. Williamson III acquired 5,500 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, May 31st. The stock was bought at an average price of $13.80 per share, for a total transaction of $75,900.00. Following the completion of the acquisition, the director now owns 42,379 shares in the company, valued at approximately $584,830.20. The disclosure for this purchase can be found here. Insiders purchased 30,814 shares of company stock worth $385,487 over the last ninety days. Corporate insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors have recently modified their holdings of CATX. Janus Henderson Group PLC purchased a new position in Perspective Therapeutics in the first quarter worth approximately $15,511,000. Affinity Asset Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth $6,069,000. Vanguard Group Inc. grew its stake in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. HighTower Advisors LLC purchased a new position in Perspective Therapeutics in the third quarter valued at $314,000. Finally, Virtu Financial LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at $138,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Recommended Stories

Analyst Recommendations for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.